Increase in the volume of an organ or tissue due to the enlargement of its component cells
POPULARITY
3 episodes with hypertrophic
4 episodes with hypertrophic
4 episodes with hypertrophic
4 episodes with hypertrophic
4 episodes with hypertrophic
3 episodes with hypertrophic
2 episodes with hypertrophic
2 episodes with hypertrophic
2 episodes with hypertrophic
In this episode, we review the high-yield topic Hypertrophic & Keloid Scars from the Dermatology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, we review the high-yield topic of Hypertrophic Scars and Keloids from the Dermatology section.FollowMedbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Tim Tobin, CEO and Founder of Planatome, has a background in the semiconductor industry where precision polishing techniques were developed. Planatome has used that technology to create molecularly smooth scalpel blades that remove all the jagged edges on traditional surgical scalpels. These new nano polished blades significantly reduce scarring and inflammation from incisions and improve healing outcomes for patients, especially those with darker skin tones who are more prone to hypertrophic scarring. The challenge is disrupting an industry that has not changed in over 100 years and that has been driven by reducing the costs, not improving the blade. Tim explains, "So we picked the surgical scalpel because it's still the foundation, the primary incision tool, whether it's a minimally invasive procedure or a procedure with a lot of cutting. So we started with that. We've since applied our technology to many other surgical instruments. We started with the scalpel, which was patented in 1915. There's been no change, no technological change, just change to drag down the cost. So it's just completely commoditized, a scalpel blade somewhere in the 20 to 50 cent range, and nobody thinks about it because everybody just uses a scalpel, and they don't need to be more critical." "So we started looking, and if you look at a scalpel blade underneath magnification, it looks almost like it's highly serrated and jagged because they're made by taking a piece of stainless steel, and they grind it up to a point, and that's the cutting edge. But they leave it like that." "We took that, and we said, okay, well, what if we polish it and take out all of those jagged serrations, at least a thousand times smoother. Now if you measure the surface, it changes the cutting mechanism from tearing and snagging to a nice clean incision. So some of the challenges in that is when surgeons have been using the same thing pretty much their whole career, when they try something different, that's not always something they want to think about." #Planatome #MedTech #MedicalDevice #Surgery planatome.com Download the transcript here
Tim Tobin, CEO and Founder of Planatome, has a background in the semiconductor industry where precision polishing techniques were developed. Planatome has used that technology to create molecularly smooth scalpel blades that remove all the jagged edges on traditional surgical scalpels. These new nano polished blades significantly reduce scarring and inflammation from incisions and improve healing outcomes for patients, especially those with darker skin tones who are more prone to hypertrophic scarring. The challenge is disrupting an industry that has not changed in over 100 years and that has been driven by reducing the costs, not improving the blade. Tim explains, "So we picked the surgical scalpel because it's still the foundation, the primary incision tool, whether it's a minimally invasive procedure or a procedure with a lot of cutting. So we started with that. We've since applied our technology to many other surgical instruments. We started with the scalpel, which was patented in 1915. There's been no change, no technological change, just change to drag down the cost. So it's just completely commoditized, a scalpel blade somewhere in the 20 to 50 cent range, and nobody thinks about it because everybody just uses a scalpel, and they don't need to be more critical." "So we started looking, and if you look at a scalpel blade underneath magnification, it looks almost like it's highly serrated and jagged because they're made by taking a piece of stainless steel, and they grind it up to a point, and that's the cutting edge. But they leave it like that." "We took that, and we said, okay, well, what if we polish it and take out all of those jagged serrations, at least a thousand times smoother. Now if you measure the surface, it changes the cutting mechanism from tearing and snagging to a nice clean incision. So some of the challenges in that is when surgeons have been using the same thing pretty much their whole career, when they try something different, that's not always something they want to think about." #Planatome #MedTech #MedicalDevice #Surgery planatome.com Listen to the podcast here
Host: Darryl S. Chutka, M.D. Guest: Jeffrey B. Geske, M.D. Hypertrophic cardiomyopathy affects 1 in 500 adults or about 600,000 individuals in the U.S. and represents the most common inherited cardiomyopathy. It often goes undetected, and it's estimated that about 85% of those with the condition remain undiagnosed. HCM can produce a variety of symptoms, the most serious being sudden death. The topic for this podcast is Hypertrophic Cardiomyopathy. What are the clues that might make us suspect a patient has HCM and how should we confirm the diagnosis? Are we able to prevent sudden death in patients with the condition and finally, what is the most effective treatment? I'll asking these questions of my guest, Jeffrey B. Geske, M.D., from the Department of Cardiovascular Diseases at Mayo Clinic. For more information on heart health, check out Mayo Clinic Talks: Heart Health | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development
This episode covers hypertrophic obstructive cardiomyopathy.Written notes can be found at https://zerotofinals.com/paediatrics/cardiology/hypertrophicobstructivecardiomyopathy/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.
Hypertrophic cardiomyopathy (or HCM for short) is a serious heart condition that involves thickening of the heart muscle wall and disruption of the normal tissue architecture, called ‘disarray'. This can result in sudden cardiac death caused by abnormal heart rhythms, known as arrhythmias. Identifying those HCM patients who are most at risk could permit preventative measures, such as implanting a cardioverter-defibrillator, which could potentially be lifesaving. However, current techniques to predict the risk of sudden death in HCM are limited, leaving patients underserved. In a recent study, Dr Richard Saumarez, an academic cardiologist formerly of the University of Cambridge, and colleagues, questioned whether conventional methods, which consider risk factors such as family history of sudden death or the degree of heart muscle thickening, are effective in predicting sudden death in HCM patients. Their research suggests that risk factor assessments might miss crucial information about the heart's electrical behaviour, which could provide more accurate clues about the risk of sudden death. As an alternative, the researchers propose direct heart-investigation methods, called electrophysiological techniques, as a more reliable assessment. Although the study was concerned with HCM, the arguments put forward are more general and applicable to other diseases, particularly to survivors of myocardial infarcts who are also at risk of sudden death.
Send us a textIt's already Episode 20 of Season 2 as we roll into winter 2024.Again this week the boy's are lucky to have two Guests Bethany Keime and Charlie Kirkman, both have different heart conditions, Bathany and twin sister Hannah both suffer from Hypertropic Cardiomyopathy whilst Charlie has Arrhythmia.Hypertrophic cardiomyopathy is a condition in which muscle tissues of the heart become thickened without an obvious cause. The parts of the heart most commonly affected are the interventricular septum and the ventricles.This is is most often caused by abnormal genes in the heart muscle. These genes cause the walls of the heart chamber (left ventricle) to become thicker than normal. The thickened walls may become stiff and this can reduce the amount of blood taken in and pumped out to the body with each heartbeat.How is hypertrophic cardiomyopathy treated?Activity limits. ...Preventing dehydration. ...Medicines to treat shortness of breath and chest pain. ...Medicines to help prevent abnormal heart rhythms. ...Anticoagulants. ...Septal myectomy. ...Alcohol septal ablation. ...Implantable cardioverter defibrillator (ICD).An Arrhythmia, or irregular heartbeat, is a problem with the rhythm or rate of your heartbeat. Your heart may beat too quickly, too slowly, or with an irregular rhythm. It is normal for your heart rate to speed up during physical activity and to slow down while resting or sleeping but with Arrhythmia this can be irregular anytime.While Arrhythmias can be a serious condition that can affect your health, there are also treatments available to help. By following a treatment plan and making heart healthy lifestyle changes, you can learn how to live with a cardiac arrhythmia.In today's Interview Bethany & Charlie tell us openly and honestly about their conditions from diagnosis to how the deal with it today and in everyday life.Bethany & sister Hannah are two remarkable twins who have taken this illness head on and realised there are others like themselves undiagnosed. Their experience as young teenagers soon discovered there was little information available and resorted to Google to explore their condition. Social Media Patient Community did not exist, so Bethany & Hannah set about correcting this by starting their own Social media presence "Heart Charged" in hope to reach out to those with this condition and those still to be diagnosed.They made us aware that as young women it was hard to get healthcare professionals to take them seriously with their health issues, simply sidelining them and saying "It's all part of growing up as a young Women" It wasn't until a member of the family discovered they had hypertrophic cardiomyopathy that both Bethany & Hannah were then checked for this Condition.These young women have gone from strength to strength and this is how they met Charlie through Their social media connections and recent success with the "Sudden Cardiac Art" Exhibition in the UK, now destined for Southern California.#getheartcharged#charliekirkman# Stroke# Subarachnoid hemorrhage#Mediastinal Germ Cell Tumour#Prostate Cancer#Bronchiectasis#CharcotmarietoothDisease#Emphysema#The after life#Ghosts#Spirts#Ouija boards#Mediums#Psychics#Reincarnation#HeartTransplant#EbsteinsAnomaly#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#HealthcareCheck out our website at www.whostomanddick.com
Today we're going to be talking about two different ways to train. Hypertrophic training and neuromuscular adaptive training. These are two fancy ways to say bulky training and ripped training. Here's the thing. Many people have it backwards and are training themselves to be lean when they want to be bulky and vice versa. Today we're gonna set the record straight so you can reach your gym goals more efficiently. --- Support this podcast: https://podcasters.spotify.com/pod/show/generalfitnesscompany/support
Message our hosts, Kieran and Jose.Hypertrophic cardiomyopathy (HCM) affects 1 in 7 cats overall, and has huge implications for feline health and wellbeing across the globe. Strategies to detect early disease are fundamentally important to both pet owners and cat breeders, so that individual animals and the wider breed can be cared for as needed. Screening for HCM in apparently healthy cats has become a hot topic, and who could be better to join Jose and Kieran for a discussion on that subject than Prof Jens Häggström? Jens is leader of the internationally recognised PawPeds echo screening programme, and originator of the some of the largest studies on feline disease ever published. Listen in as he shares insights into their most recent data and his opinions on how best to approach screening for early disease.
AI Meets Cardiology: Innovation at UCSD Detects Hidden Killer and Opens Door to Early Interventions Host Beth Friedman talks with Dr. Jorge Silva, Cardiologist, Professor, and Director of the Hypertrophic Cardiomyopathy Program at UC San Diego Health. Their conversation uncovers a new AI tool being used at UCSD to help cardiologists identify a hidden killer – hypertrophic cardiomyopathy. It's one of healthcare's most misleading and under-diagnosed conditions….and also the #1 cause of cardiovascular death in people under the age of 35. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/
Dr. Justin Abbatemarco and Dr. Jiyeon Son discuss her paper "Association between Radiographic Features of Hypertrophic Pachymeningitis and its Underlying Diagnoses." Show reference: https://www.aan.com/conferences-community/summer-conference/abstracts/ This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
In the latest episode of Anabolic Radio I had the pleasure of chatting with @borgefagreli who is the creator of Myo-Reps.Myo Reps is a hybrid of rest pause and cluster set training. Just like the variety of different training techniques we can implement, it is another tool in the toolbox and as we know there are many ways to Rome..We touch on how you can practically implement it, the thought process behind it, in addition to some interesting data coming out of University of Tampa investigating the use of Myo-Reps.Links: https://linktr.ee/ishak_ishakSupport the show
In today's episode we take you through our approach to a disease with a wide array of clinical presentations and evolving treatment landscape - hypertrophic obstructive cardiomyopathy. Written by: Dr. Kate Haichin (Internal Medicine Resident) Reviewed by: Dr. Michael Chetrit (Cardiologist) & Dr. John Angelopoulos (General Internist) Support the show
Virginia Gov. Glenn Youngkin has officially recognized Feb. 28 as Hypertrophic Cardiomyopathy Awareness Day. The day of recognition is designed to raise awareness about the condition of hypertrophic cardiomyopathy and to help educate people about the risks and benefits of managing this condition. Hypertrophic cardiomyopathy is a chronic cardiovascular disease in which the heart muscle thickens. It can impact a person's overall health significantly, leading to an increased risk of heart failure, stroke, atrial fibrillation, and even sudden cardiac death. According to the governor's office, an estimated 700,000 to 1,650,000 people in the United States live with hypertrophic cardiomyopathy, yet...Article LinkSupport the show
Friedreich's ataxia is a rare, genetic, degenerative disorder that affects multiple systems in the body. As the disease progresses, patients typically experience various heart conditions. Hypertrophic cardiomyopathy, fibrosis, heart failure, and arrhythmias are the cause of death in approximately two-thirds of Friedreich's ataxia patients. Lexeo Therapeutics is developing a gene therapy to treat FA cardiomyopathy. We spoke to R. Nolan Townsend, CEO of Lexeo Therapeutics, about Friedreich's ataxia, the company's gene therapy in development, and its pursuit of gene therapies for both rare and common diseases.
Hypertrophic cardiomyopathy is a rare, genetic heart condition that has a disproportionate impact on people in the Black community because of socio-economic and access issues. Cytonkinetic's experimental therapy aficamten is in late-stage development to treat the condition, but it also reflects a long-term focus of the company to address health inequities. We spoke to Robert Blum, CEO of Cytokinetics, about hypertrophic cardiomyopathy, how the company has worked to build relationships in the black community to expand participation in clinical trials, and how it is thinking ahead to issues of access and affordability as it advances the drug towards the market.
Hypertrophic and keloid scars are common skin conditions resulting from abnormal wound healing. One possible treatment involves the use of a laser and a new Cochrane Review of the evidence was published in September 2022. We asked one of the authors, Ana Carolina Nunes from Cochrane Brazil in Sao Paolo, to tell us more in this podcast.
Hypertrophic and keloid scars are common skin conditions resulting from abnormal wound healing. One possible treatment involves the use of a laser and a new Cochrane Review of the evidence was published in September 2022. We asked one of the authors, Ana Carolina Nunes from Cochrane Brazil in Sao Paolo, to tell us more in this podcast.
Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.
Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.
Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.
Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.
Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.
Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.
In 2017 Brad started experiencing multiple falls that became concerning. He went to get checked out and discovered there was a baseball sized tumor growing on his brainstem. This tumor was a meningioma that had been growing for decades, possibly upwards of 30 years. As Brad was rushed to surgery, […]
Commentary by Dr. Valentin Fuster
This podcast episode explores new advances in treating obstructive hypertrophic cardiomyopathy (HCM) and the role of myosin inhibitors, and provides an overview of the EXPLORER-HCM and VALOR-HCM clinical trials. Iacopo Olivotto, University of Florence, Italy, first discusses unmet medical needs, specifically regarding the unmet needs of patients and gaps in current treatment methods. The discussion then centres around the mechanism of action of myosin inhibitors, a first-in-class drug for HCM, recently approved by the European Medicines Agency (EMA). The findings of current clinical trials are outlined, with results being linked to a reduced need for septal reduction therapy, in addition to improved quality of life for patients. Finally, case studies are presented, discussing the impact of treatments on the lives of patients with HCM, and how to best integrate new treatments into current practice.
CardioNerds (Drs. Amit Goyal and Dan Ambinder) join Dr. Mina Fares, Dr. Johannes Bergehr, and Dr. Christina Peter from Cambridge University Hospitals in the UK. They discuss a case involving a man man in his 40's presented with progressive heart failure symptoms. He has extensive background cardiac history including prior episodes of myocarditis and complete heart block status post permanent pacemaker implantation. Ultimately a diagnosis of Danon disease is made. Dr. Sharon Wilson provides the E-CPR for this episode. Audio editing by CardioNerds Academy Intern, Hirsh Elhence. CardioNerds is collaborating with Radcliffe Cardiology and US Cardiology Review journal (USC) for a ‘call for cases', with the intention to co-publish high impact cardiovascular case reports, subject to double-blind peer review. Case Reports that are accepted in USC journal and published as the version of record (VOR), will also be indexed in Scopus and the Directory of Open Access Journals (DOAJ). CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Summary - A Presentation of Heart Failure and Heart Block with Elusive Genetic Origins - Cambridge University A man in his 40s with a history of cardiac issues, including prior myocarditis and complete heart block, presented with progressive heart failure symptoms. Extensive cardiac investigations were conducted, revealing dilated left ventricle, mild to moderate left ventricular systolic dysfunction, normal coronaries, infero-lateral late gadolinium enhancement on cardiac MRI, and low-level uptake on PET-CT. Differential diagnosis included worsening underlying cardiomyopathy, recurrent myocarditis, tachycardia-related cardiomyopathy, pacemaker-induced LV dysfunction, and sarcoidosis. The patient's condition improved with heart failure medications, and cardiac MRI showed a mildly dilated left ventricle with moderate systolic dysfunction and active inflammation in the anterior wall. Further evaluation indicated a family history of hereditary cardiomyopathy, and the patient exhibited phenotypic features such as early-onset heart disease, arrhythmias, family history of cardiomyopathy, learning problems, intellectual disability, and mild proximal myopathy. Genetic testing confirmed a LAMP2 mutation, leading to the diagnosis of Danon disease. Case Media - A Presentation of Heart Failure and Heart Block with Elusive Genetic Origins - Cambridge University Show Notes -A Presentation of Heart Failure and Heart Block with Elusive Genetic Origins - Cambridge University References - Danon, M. J., Oh, S. J., DiMauro, S., Miranda, A., De Vivo, D. C., & Rowland, L. P. (1981). Lysosomal glycogen storage disease with normal acid maltase. Neurology, 31(1), 51-7. Nishino, I., Fu, J., Tanji, K., Nonaka, I., & Ozawa, T. (2000). Mutations in the gene encoding LAMP2 cause Danon disease. Nature, 406(6798), 906-10. Tanaka, K., Nishino, I., Nonaka, I., Fu, J., & Ozawa, T. (2000). Danon disease is caused by mutations in the gene encoding LAMP2, a lysosomal membrane protein. Nature, 406(6798), 902-6. Maron, B. J., Haas, T. S., Ackerman, M. J., Ahluwalia, A., Spirito, P., Nishino, I., ... & Seidman, C. E. (2009). Hypertrophic cardiomyopathy and sudden death in a family with Danon disease. JAMA, 301(12), 1253-9. Hashem, S., Zhang, J., Zhang, Y., Wang, H., Zhang, H., Liu, L., ... & Wang, J. (2015). AAV-mediated gene transfer of LAMP2 improves cardiac function in Danon disease mice. Stem cells, 33(11), 2343-2350. Chi, L., Wang, H., Zhang, J., Zhang, Y., Liu, L., Wang, J., ... & Hashem, S. (2019). CRISPR/Cas9-mediated gene editing of LAMP2 in patient-derived iPSCs ameliorates Danon disease phenotypes.
On the 73rd Episode of The Paul Cardall Podcast, HeartCharged Executives Hannah and her sister Bethany Keime talk about their personal experience with Hypertrophic cardiomyopathy (HCM) and what they're doing to help others live longer. Their disease is a common cause of sudden deaths among athletes. Paul, Bethany, and Hannah describe the disease and what they are doing to bring awareness and legislation to ensure a defibrillator is in every school and public building.VISIT THE OFFICIAL PODCAST WEBSITE:https://paulcardall.com/podcast ABOUT THE HEART IN HEARTCHARGED Website: http://getheartcharged.orgInstagram: https://www.instagram.com/heartchargedAccording to the HeartCharged website, “Once upon a time we were average high-school girls. Then we were diagnosed with hypertrophic cardiomyopathy (HCM), which is better than not being diagnosed but not as good as not having it. We were extremely athletic and HCM is the #1 killer of student athletes. It is asymptomatic so it most often kills without warning. But we were screened and found out we had it.” “We were immediately put on medications and made life-style changes so that our heart rates wouldn't go up causing our hearts to fibrillate causing us to die. Then the condition got worse and those precautions weren't deemed enough, so we had defibrillators implanted. The device would shock our hearts if they went out of control. Of course, we still take medications and are careful how we live.” They continue, “We are so grateful to have found out and be managing our conditions. With that gratitude, we are trying to warn the world. Childhood deaths from undiagnosed heart conditions are preventable. We can end them. But we need people prepared to act in an emergency and our children evaluated to discover these life-threatening conditions.” Because I have been given much, I too must give;Because of thy great bounty Lord, each day I live; (Grace Noll Crowell) Because we were screened and it saved our lives, we want all children to have the heart screenings they need.Because we had each other to share the day-to-day dealing with our conditions with, we want others to be able to connect with fellow heartcharged warriors and know patient-to-patient what this life means.Because we have grown with gratitude, we want to express it so others know it exists.Because our hearts still quiver, we want others to know we walk on without surety.Because there are still sorrows in the world, we want people to feel our tears.Because our souls still find joy, we want others to smile loudly.Join The JoltFollow us on Instagram @heartchargedStop preventable deaths. Prepare yourself and your community for a sudden cardiac emergency. Ensure heart conditions are found and treated.Share patient-to-patient information. Understand and embrace the HeartCharged Warrior life. ABOUT BETHANYWe of HeartCharged take great pride in our Instagram account, The Jolt @heartcharged. We consider it our home base because it is really where we started connecting with our international HeartCharged friends, and those that care for them and care about them. When you look at that account, we believe you will see a put-together page. The look is coordinated though the content is mixed. Gratitude and grace, facts and funnies, self-awareness and selfies are all apparent. Posts cover red days, blue days, happy days, what-is-happening days. You see the person, the patient, the giver, the receiver. And knowledge is unleashed so action can follow. And as is the page, so is the page's creator, the visionary who puts it all together, Bethany. Bethany will tell you herself that when she was told she needed a defibrillator implanted that she, of course, worried what it would look like. She was, and is, a dancer, earning her BFA in Dance Performance. She communicates with her body. She had already been diagnosed with HCM for 5 years when she passed out a time then two. And all of a sudden, her doctors told her one day that in 10 days she would have a defibrillator implanted.She will tell you herself about the days of doubt between the implanting and the unveiling. She spent weeks waiting for the bandages to come off to finally see who she had become. And when she saw, and it was no particularly small thing she saw especially in comparison to her small body, she looked on her new look and smiled. She did not see imperfection but strength and resiliency. And each day since, she has at her side that reminder of what is important and why it's important and why she needs to do what she does. Each piece of The Jolt page was picked with a purpose like Bethany's outfit on a Saturday night. Even the color scheme – blue, red, white, gold - has HeartCharged meanings. Beta-blocker blue, heart red, oxycodone white, winner's gold. The page is aptly named The Jolt because that is what a defibrillator sends to get someone's heart back in rhythm, and the page is ready to send a needed jolt to get someone's life back in rhythm. The first post up on The Jolt is perhaps Bethany's mission statement. It is a quote, “One day you will tell your story about how you overcame that battle you went through, and God will send you the exact people who need to hear that story.” And so on the page you will see her story. You will see her bulge in her bikini and know her battle. You will see her in a hospital gown and still grasp her glow. You will see her in leotards and lingerie, being charged or getting recharged. You may find that she flaunts her defibrillator, but she does so with a little girl's fears and a strong woman's faith. You may see her wonder and weep, strong and proud or down and out. But you will be able to see her. Her open-book approach to The Jolt page and her life makes her story just that easy to read and her battle just that easily known. Bethany has gone down a path which others are traveling and she offers to take their hand as they do. She saw herself, she accepted herself, she showed herself, she showed gratitude. She is happy to help them do the same. And now that you know her, you can walk with her as a friend. Email her at Bethany@getheartcharged.org ABOUT HANNAHIf you've seen our Instagram account, The Jolt @heartcharged, then you've already met Hannah. And you really are lucky to have met her because how many people can say they know somebody who has been shocked twice by their defibrillator while lip-syncing to Celine Dion's "All By Myself" on their high-school stage and gone on to finish the performance? (and not even mention it so she could get the pity vote and take 1st place instead of 2nd.) You've been delighted by her quirky sense of humor (sharing spaghetti a la “Lady and the Tramp” with her ‘heart' for her diagnosis anniversary). You've been treated to her dramatic prowess (was she actually the one with HCM in One Tree Hill?). You've enjoyed her editing skills, her directing talents, and her ability to really put together something out of almost nothing - all talents she is using now while studying film in college. (The Bionic Woman, what surgical instruments did they use for that implantation?). You've observed her outreach (gathering World Heart Day wishes from dozens of her HeartCharged friends around the world). You've seen her political passion (voting, campaigning, interning, trying to elect those who will support the HeartCharged cause even if it's while dancing on the streets in an apple costume). You see her putting to use the power of the spoken word (a Thespian and Spoken Word performer in high school, a tour guide, a podcast guest). You know she's done some death-defying acts (not dying in her sleep after going into sudden cardiac arrest, that's a good trick). You know she's a constant at the cardiologist (awww there she is with Dr. Avila). You know her condition is being managed by meds (and lots of them plus activity restrictions, meaning her approved sports are shuffleboard and darts). You know she has a genetic condition (same genes as her sister, aunt, mom - but they definitely look severely different in her). You know she comes at her mission to see all children receive heart screenings from a variety of angles (including standing in a pool to photograph her bionic sister in a bikini). You know she likes to dress up and put on wigs (you gotta love that, she's had to change roles plenty in life as well). And you will find that she is a person of intense faith (she spent 17 months serving a full-time ecclesiastical mission for The Church of Jesus Christ of Latter-day Saints in the honest-to-goodness best mission in the world, Utah Salt Lake City Temple Square). Meet Hannah. Love Hannah. Enjoy Hannah. We do!Email her at Hannah@getheartcharged.org LISTEN TO THE MUSIC OF PAUL CARDALLhttp://www.paulcardall.com
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.
Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.
Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.
Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.
Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.
Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.
This episode covers hypertrophic obstructive cardiomyopathy.Written notes can be found at https://zerotofinals.com/medicine/cardiology/hocm/ or in the cardiology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.
This informative podcast spotlights the current treatment landscape of hypertrophic cardiomyopathy (HCM), detailing typical diagnosis and outlining the use of echocardiography for obstructive HCM. This podcast was sponsored by Myokardia and Bristol Myers Squibb.
When Christina turned 40 she suddenly started having migraines every day. She was going to work as an accountant dealing with spreadsheets and math, while splitting headaches turned each day into relentless agony. After a month of this pain she finally went to see her doctor, who ordered an MRI. […]
ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Hypertrophic cardiomyopathy State of the art in bypass surgery Snapshots Host: Susanna Price Guests: Stephan Achenbach, Carlos Aguiar, Eugene Braunwald and Rafael Sadaba Want to watch that episode? Go to: https://esc365.escardio.org/event/812 Disclaimer: This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel, Susanna Price and Rafael Sadaba have declared that they have no potential conflicts of interest. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Eugene Braunwald has declared to have potential conflicts of interest to report: served on MyoKardia advisory committee. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.
Hypertrophic cardiomyopathy (HCM) causes thickening of the heart muscle, left ventricular stiffness, mitral valve changes and cellular changes. For many years, management of this condition was surgery or alcohol ablation. Mavacamten is the first FDA approved drug to help treat patients with HCM. Drs. Steven Nissen and Milind Desai talk about this novel treatment option and the benefits of being treated by a specialized center.
$5 Q-BANK: https://www.patreon.com/highyieldfamilymedicine Intro 0:30, Congenital GI defects overview 1:23, Esophageal atresia and tracheoesophageal fistula 2:12, VACTERL syndrome 3:39, Hypertrophic pyloric stenosis 4:29, Duodenal atresia and the "double bubble" sign 6:02, Intestinal malrotation and midgut volvulus 6:52, Annular pancreas 8:58, Jgejunal-ileal atresia 10:09, Astroschisis and omphalocele 11:10, Duplication cysts 12:19, Meckel's diverticulum 13:39, Imperforate anus 14:52, Hirschprung disease 15:49, Cystic fibrosis 16:40, Congenital pulmonary airway malformation 24:02, Pulmonary sequestration 25:08, Congenital lobar emphysema 26:04, Bronchogenic cysts 26:14, Congenital diaphragmatic hernia 26:50, Pulmonary hypoplasia 28:28, Potter syndrome 28:39, Scimitar syndrome 29:03, Laryngomalacia 29:22, Transient tachypnea of the newborn 30:02, Neonatal respiratory distress syndrome 30:31, Necrotizing enterocolitis 31:19, Practice questions 31:59
Feline Hypertrophic Cardiomyopathy in cats has long been a deadly disease with no answers. Now, thanks to research funded in part by the EveryCat Health Foundation, we are finding answers and even cures! Dr. Brian Holub joins the show to talk about the latest. Far too many Americans are homeless and it's sad to see in any city across America. Many people who are struggling with housing actually have pets and for some they are a lifeline. Dr. John Geller joins us to talk about the Street Dog Coalition, which tries to provide care for these animals. Steve answers listener questions via phone and email.
Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a collaborative care model; and Incorporate emerging therapies for managing patients with HCM based on their efficacy, safety, and ability to address the unmet needs of patients and the pathophysiology of HCM.
In this episode we will discuss Hypertrophic Olivary Degeneration (H.O.D.) once again, this time with a new guest, Brad Asher. Hypertrophic olivary degeneration (HOD) a rare neurological condition caused by degeneration in the brain stem, the structure that connects the brain to the spinal cord. Signs and symptoms include palatal tremors, lack of movement coordination (ataxia), Holmes tremor, vision problems, muscle weakness, and gait impairment, along with an MRI showing enlargement (hypertrophy) of the inferior olivary nucleus. (CREDITS: NORD) Brad managed Health Clubs for 20 years and sold commercial and personal lines of Insurance for 20 years as well. He retired because of HOD at age 59.
In Episode 3.9, Lauren and JJ investigate a case of dyspnea in a cat patient. This episode includes a complete review of hypertrophic cardiomyopathy in the cat. References: (1) Lake-Bakaar, G. & Kittleson, M. D. (2017). Cardiomyopathy, hypertrophic (feline). VINcyclopedia. www.vin.com (2) Stern, J. (2019). Hypertrophic cardiomyopathy and co-managing hypertension or hyperthyroidism. American Association of Feline Practitioners Conference Proceedings. (3) Kittleson, M. D. (2021). The feline cardiomyopathies: 2. Hypertrophic cardiomyopathy. Journal of Feline Medicine and Surgery, 23(11), pp 1028-1051. (4) Pereira, Y. M. (2018). Approach to the dyspnoeic cat. British Small Animal Veterinary Conference Proceedings. (5) Rothrock, K. & Shell, L. (2021). Pulmonary edema (feline). VINcyclopedia. www.vin.com (6) Rishniw, M. (2017). Feline heart size and hypertrophy. VIN Medical FAQs. www.vin.com (7) Lisciandro, G. R. (2015). Lung ultrasound in small animals: The vet blue. American College of Veterinary Internal Medicine Conference Proceedings. (8) Brister, J. (2018). Heart failure, left-sided (feline). VINcyclopedia. www.vin.com (9) Rishniw, M. (2017). Furosemide trial. VIN Medical FAQs. www.vin.com (10) Rishniw, M. (2017). Feline murmurs and gallop sounds: A quick primer. VIN Medical FAQs. www.vin.com (11) Campbell, F. E. (2013). Cardiac disease and examination. World Small Animal Veterinary Association World Congress Proceedings.
In this episode, we review the high-yield topic of Hypertrophic & Keloid Scars from the Dermatology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
On today's show we are speaking with Christina Coates about Hypertrophic olivary degeneration (HOD) a rare neurological condition caused by degeneration in the brain stem, the structure that connects the brain to the spinal cord. Signs and symptoms include palatal tremors, lack of movement coordination (ataxia), Holmes tremor, vision problems, muscle weakness, and gait impairment, along with an MRI showing enlargement (hypertrophy) of the inferior olivary nucleus. (CREDITS: NORD) In 2017, Christina was diagnosed with a small Cavernous Malformation with a previous hemorrhage in her cerebellum. In 2021, she had a craniotomy to remove the malformation, and developed HOD on her medulla. Her symptoms began a few months after the Cavernoma resection. Creating HODA is a passion project for Christina, with the hope of replicating the success of The Angioma Alliance. Christina has worked in Accounting and Finance for her entire career and enjoys her volunteer work with the Arizona chapter of the Angioma Alliance. Christina relishes the opportunities she has to attend and support the Arizona Cardinals, reading, and outdoors activities as her symptoms permit.
© 2020-2025 Ivy Podcast Discovery LLC
